Business
Elanco Innovation Builds Momentum, Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Reaches Blockbuster Status
Elanco Animal Health Incorporated (NYSE: ELAN) has announced significant advancements with its two most recent pet health innovations—Credelio Quattro and Zenrelia—further demonstrating the company's commitment to helping pet owners and veterinarians around the world go beyond today's standard of treatment.
About this update from Elanco Animal Health Incorporated
[{"type":"list","items":[{"val":[{"type":"text","content":"Credelio Quattro marked $100 million in net sales making it Elanco's fastest pet health blockbuster in history and one of the industry's fastest ever, especially with a single geographic approval","length":203,"tagName":"p"}]},{"val":[{"type":"text","content":"Credelio Quattro joins Experior® as Elanco's second of six recently launched blockbuster-potential products to reach the $100 million annual net sales milestone","length":169,"tagName":"p"}]},{"val":[{"type":"text","content":"Zenrelia™ (ilunocitinib tablets) now in market in the European Union (EU) and Great Britain","length":91,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":463,"olType":false},{"type":"text","content":"GREENFIELD, Ind., Sept. 8, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) has announced significant advancements with its two most recent pet health innovations—Credelio Quattro and Zenrelia—further demonstrating the company's commitment to helping pet owners and veterinarians around the world go beyond today's standard of treatment.","length":364,"tagName":"p"},{"type":"image","alt":"Elanco logo (PRNewsfoto/Elanco Animal Health)","displaySize":"","headline":null,"caption":"Elanco logo (PRNewsfoto/Elanco Animal Health)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":267,"url":"https://media.zenfs.com/en/prnewswire.com/3e0d7ba65d33b7150e97f71c77abc8af"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LM_acgCT_vHsVMsjwpFxgA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ3MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/3e0d7ba65d33b7150e97f71c77abc8af","width":400,"height":267}},"href":"https://mma.prnewswire.com/media/2309278/Elanco_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Credelio Quattro, Elanco's latest parasite innovation brought to market, became Elanco's fastest pet health blockbuster in history and one of the industry's fastest ever, especially with a single geographic approval, reaching blockbuster status of $100 million in net sales in less than eight months. Credelio Quattro offers the broadesti parasite protection available in an isoxazoline endectocide covering six types of parasites—fleas, ticks, heartworm disease, and three risky intestinal parasites—roundworms, hook...